Henry Schein, Inc. (NASDAQ:HSIC) Receives $85.58 Consensus Target Price from Analysts

Shares of Henry Schein, Inc. (NASDAQ:HSIC) have received a consensus recommendation of “Hold” from the thirteen analysts that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, six have issued a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month target price among brokers that have covered the stock in the last year is $85.5833.

A number of equities research analysts recently weighed in on HSIC shares. Robert W. Baird set a $100.00 price objective on Henry Schein and gave the company an “outperform” rating in a research report on Monday, February 23rd. Mizuho boosted their target price on shares of Henry Schein from $81.00 to $88.00 and gave the stock a “neutral” rating in a report on Wednesday, February 25th. Weiss Ratings restated a “hold (c)” rating on shares of Henry Schein in a report on Monday, December 29th. JPMorgan Chase & Co. lifted their price objective on shares of Henry Schein from $78.00 to $92.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 25th. Finally, Wall Street Zen lowered shares of Henry Schein from a “strong-buy” rating to a “buy” rating in a research note on Saturday.

Insiders Place Their Bets

In related news, Director Philip A. Laskawy sold 2,844 shares of the business’s stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $80.36, for a total transaction of $228,543.84. Following the transaction, the director directly owned 21,961 shares in the company, valued at $1,764,785.96. The trade was a 11.47% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Kurt P. Kuehn sold 2,844 shares of the company’s stock in a transaction dated Tuesday, March 10th. The shares were sold at an average price of $78.96, for a total value of $224,562.24. Following the transaction, the director directly owned 15,420 shares in the company, valued at $1,217,563.20. This represents a 15.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 104,556 shares of company stock worth $8,476,351 over the last quarter. Company insiders own 1.14% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. AQR Capital Management LLC lifted its stake in shares of Henry Schein by 47.3% during the first quarter. AQR Capital Management LLC now owns 30,402 shares of the company’s stock worth $2,071,000 after buying an additional 9,756 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Henry Schein by 1.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 16,859 shares of the company’s stock worth $1,155,000 after acquiring an additional 229 shares during the last quarter. Acadian Asset Management LLC acquired a new stake in Henry Schein during the 1st quarter worth about $676,000. Envestnet Asset Management Inc. grew its stake in Henry Schein by 103.1% during the 2nd quarter. Envestnet Asset Management Inc. now owns 91,299 shares of the company’s stock valued at $6,669,000 after purchasing an additional 46,357 shares during the last quarter. Finally, Resona Asset Management Co. Ltd. grew its stake in Henry Schein by 22.9% during the 2nd quarter. Resona Asset Management Co. Ltd. now owns 1,435 shares of the company’s stock valued at $105,000 after purchasing an additional 267 shares during the last quarter. Institutional investors and hedge funds own 96.62% of the company’s stock.

Henry Schein Stock Performance

Shares of NASDAQ:HSIC opened at $74.61 on Thursday. The firm has a 50 day moving average of $78.13 and a 200 day moving average of $72.93. The company has a quick ratio of 0.76, a current ratio of 1.38 and a debt-to-equity ratio of 0.59. The company has a market capitalization of $8.56 billion, a price-to-earnings ratio of 22.82, a price-to-earnings-growth ratio of 2.24 and a beta of 0.87. Henry Schein has a 52 week low of $60.56 and a 52 week high of $89.29.

Henry Schein (NASDAQ:HSIC) last announced its earnings results on Tuesday, February 24th. The company reported $1.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.30 by $0.04. Henry Schein had a return on equity of 15.16% and a net margin of 3.02%.The business had revenue of $3.44 billion for the quarter, compared to analysts’ expectations of $3.34 billion. During the same quarter last year, the firm earned $1.19 EPS. The business’s revenue for the quarter was up 7.7% on a year-over-year basis. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. On average, sell-side analysts predict that Henry Schein will post 4.74 earnings per share for the current fiscal year.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.